新型葡萄球菌表面相关蛋白疫苗对奶牛金黄色葡萄球菌及非金黄色葡萄球菌性乳腺炎的效力
本研究纳入45头妊娠荷斯坦奶牛,随机分为SASP疫苗组(n=15)、SCSP疫苗组(n=16)和未接种对照组(n=14),在自然暴露条件下评估疫苗对金黄色葡萄球菌及非金黄色葡萄球菌性乳腺炎的效力。SCSP疫苗显著降低了葡萄球菌性乳腺炎发生率,两种疫苗均诱导了血清和乳中抗体滴度升高,但免疫持续时间约四个月。结论认为SASP和SCSP疫苗提供了部分保护。
要点
- SCSP疫苗显著降低葡萄球菌性乳腺炎发生率,SASP疫苗效果未明确。
- 接种奶牛血清和乳中抗SASP及抗SCSP抗体滴度均高于未接种对照组。
- 抗体滴度在泌乳约120天时下降,免疫持续时间约四个月。
核心结论
- SASP和SCSP疫苗对自然感染提供了部分保护。
研究设计与样本
- 妊娠荷斯坦奶牛(n=45)随机分为SASP疫苗组(n=15)、SCSP疫苗组(n=16)和未接种对照组(n=14),在自然暴露条件下监测整个300天泌乳期。
- 疫苗含1.2 mg SASP或SCSP及Emulsigen-D佐剂,对照组注射磷酸盐缓冲液加Emulsigen-D佐剂;于预期产犊前60、40、20天皮下接种三次,泌乳120天和240天加强免疫。
主要发现
- SCSP疫苗显著降低了葡萄球菌性乳腺炎发生率。
- 接种奶牛血清和乳中抗SASP及抗SCSP抗体滴度高于未接种对照组。
- 抗SASP和抗SCSP抗体滴度在泌乳约120天时下降,表明免疫持续时间约四个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mastitis is an inflammation of the mammary gland commonly caused by bacteria or fungi. Staphylococcus aureus is a major bacterium that causes mastitis in dairy cows. Non-aureus staphylococci are also increasingly reported, with Staphylococcus chromogenes being the most common species. Current staphylococcal mastitis control programs are not fully effective, and treatment with antibiotics is not sustainable. Non-antibiotic sustainable control tools, such as effective vaccines, are critically needed. We previously developed S. aureus surface-associated proteins (SASP) and S. chromogenes surface-associated proteins (SCSP) vaccines that conferred partial protective effects. We hypothesized that vaccination with SASP or SCSP would reduce the incidence of S. aureus mastitis throughout the lactation period. The objective of this study was to evaluate the efficacy of SASP and SCSP vaccines against S. aureus and non-aureus staphylococcal mastitis under natural exposure over 300 days of lactation. Pregnant Holstein dairy cows (n = 45) were enrolled and assigned to receive SASP (n = 15) or SCSP (n = 16) vaccines or unvaccinated control (n = 14). Cows were vaccinated with 1.2 mg of SASP or SCSP with Emulsigen-D adjuvant. Control cows were injected with phosphate-buffered saline with Emulsigen-D adjuvant. Three vaccine injections were given subcutaneously at 60, 40, and 20 days before the expected calving. Booster vaccinations were given at 120 and 240 days in milk. Cows were monitored for mastitis at quarter and cow levels, staphylococcal mastitis incidence, changes in serum and milk anti-SASP and anti-SCSP antibody titers, bacterial counts in milk, adverse reactions, milk yield and milk somatic cells count over 300 days of lactation. The SCSP vaccine conferred a significant reduction in the incidence of staphylococcal mastitis. Milk and serum anti-SASP and anti-SCSP antibody titers were increased in the vaccinated cows compared to unvaccinated control cows. Anti-SASP and anti-SCSP antibody titers decreased at about 120 days in milk, indicating the duration of immunity of about four months. In conclusion, the SASP and SCSP vaccines conferred partial protection from natural infection.
引用
- Vidlund J, Gelalcha BD, Gillespie BE, et al. Efficacy of novel staphylococcal surface associated protein vaccines against Staphylococcus aureus and non-aureus staphylococcal mastitis in dairy cows. Vaccine. 2024. PMID: 38281900. doi:10.1016/j.vaccine.2024.01.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。